Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03429244 · ClinicalTrials.gov registry record · Phase 2
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT03429244 is a Phase 2 study of Prostate Cancer that has completed, run by Indiana University. The registered enrollment target is 36 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT03429244, a Phase 2 study of Prostate Cancer, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
The overall objective of this Early Phase Clinical Trial is to begin defining the accuracy of 68Ga-PSMA-11 for detecting the location and size of clinically significant prostate cancer lesions in low and intermediate risk disease. A molecularly-targeted probe (68Ga-PSMA-11), coupled with an advanced clinical imaging system (Siemens Biograph VisionPET-CT), will improve accuracy during biopsy and staging. We propose detailed intra-lesion whole-mount pathologic analysis as the gold standard for critically assessing PSMA PET accuracy in patients undergoing surgery, and blinded PSMA PET-CT comparison with standard multi-parametric MRI (mpMRI) for patients having biopsy on active surveillance. This intensive testing of the accuracy and value of PSMA-based tracers requires our unique collaboration of surgeons, radiologists, pathologists, and imaging scientists with decades of experience and innovation.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 68Ga-PSMA-11 PET-MRI
Study Locations (4)
Indiana
- Indiana University Health North Hospital - Carmel
- Indiana University Health Hospital - Indianapolis
- Indiana University Health Methodist Hospital - Indianapolis
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2022-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03429244
The ClinicalTrials.gov registry entry for NCT03429244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-PSMA-11 PET-MRI is the first listed.
NCT03429244 reports 4 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT03429244 about?
NCT03429244 is a clinical study titled "PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer". The overall objective of this Early Phase Clinical Trial is to begin defining the accuracy of 68Ga-PSMA-11 for detecting the location and size of clinically significant prostate cancer lesions in low and intermediate risk disease. A molecularly-targeted probe (68Ga-PSMA-11), coupled with an advance...
What is the current status of trial NCT03429244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2019-04-15. Estimated completion is 2022-05-01.
What conditions does trial NCT03429244 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03429244?
The interventions under investigation include: 68Ga-PSMA-11 PET-MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03429244?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03429244 being conducted?
This trial has 4 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.